➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
McKesson
Boehringer Ingelheim
Colorcon
Express Scripts

Last Updated: June 16, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for D-Proline


Email this page to a colleague

« Back to Dashboard

What is the drug development status for D-Proline?

D-Proline is an investigational drug.

There have been 4 clinical trials for D-Proline. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2015.

The most common disease conditions in clinical trials are Polycythemia Vera, Polycythemia, and Leukemia, Myelogenous, Chronic, BCR-ABL Positive. The leading clinical trial sponsors are AOP Orphan Pharmaceuticals AG, Fondazione per la Ricerca Ospedale Maggiore, and PharmaEssentia Corporation (Co-Sponsor for USA).

There is one US patent protecting this investigational drug and ten international patents.

Recent Clinical Trials for D-Proline
TitleSponsorPhase
ENDURE - Efficacy and Safety of AOP2014 With CML Patients in RemissionAOP Orphan Pharmaceuticals AGPhase 2
ENDURE - Efficacy and Safety of AOP2014 With CML Patients in RemissionDeutsche Krebshilfe e.V., Bonn (Germany)Phase 2
ENDURE - Efficacy and Safety of AOP2014 With CML Patients in RemissionPhilipps University Marburg Medical CenterPhase 2

See all D-Proline clinical trials

Clinical Trial Summary for D-Proline

Top disease conditions for D-Proline
Top clinical trial sponsors for D-Proline

See all D-Proline clinical trials

US Patents for D-Proline

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
D-Proline   Get Started Free Template-fixed peptidomimetics POLYPHOR LTD. (Allschwil, CH)   Get Started Free
D-Proline   Get Started Free Generation of cytotoxic tumor specific cell lines and uses thereof Ramot at Tel-Aviv University Ltd. (Tel-Aviv, IL)   Get Started Free
D-Proline   Get Started Free Nuclear targeting sequences Yeda Research and Development Co. Ltd. (Rehovot, IL)   Get Started Free
D-Proline   Get Started Free Self-assembled Fmoc-ff hydrogels Romat at Tel-Aviv University Ltd. (Tel-Aviv, IL)   Get Started Free
D-Proline   Get Started Free Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for D-Proline

Drugname Country Document Number Estimated Expiration Related US Patent
D-Proline Australia AU2007345497 2027-01-29   Get Started Free
D-Proline Canada CA2676865 2027-01-29   Get Started Free
D-Proline European Patent Office EP2114986 2027-01-29   Get Started Free
D-Proline Spain ES2425575 2027-01-29   Get Started Free
D-Proline World Intellectual Property Organization (WIPO) WO2008092281 2027-01-29   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Medtronic
Moodys
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.